NAD(P)H quinone oxidoreductase 1 (NQO1) genetic C609T polymorphism is associated with the risk of digestive tract cancer: A meta-analysis based on 21 case-control studies

European Journal of Cancer Prevention

Volumn 21, Issue 5, 2012, Pages 432-441

  Yang, Fei Yun ^a   Guan, Qing Kai ^a   Cui, Yan Hui ^a   Zhao, Zhi Qiang ^a   Rao, Wang ^a   Xi, Zan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

colorectal cancer; esophageal cancer; gastric cancer; genetic polymorphism; meta analysis; NAD(P)H quinone oxidoreductase 1

Indexed keywords

NAD(P)H QUINONE OXIDOREDUCTASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ALLELE; ARTICLE; ASIAN; CALCULATION; CANCER RISK; CHINESE; COLORECTAL CANCER; CONFIDENCE INTERVAL; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; EMBASE; ESOPHAGUS CANCER; ETHNICITY; EUROPEAN UNION; GENETIC HETEROGENEITY; GERMANY; HUMAN; INDIAN; JAPANESE; MEDLINE; META ANALYSIS; NAD(P)H QUINONE OXIDOREDUCTASE 1 GENE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TUMOR GENE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 84864353756     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834f7514     Document Type: Article

References (51)

1. Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y, Kaya BY, et al. (2010). No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev 11:1051-1058.
2. Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297-303. (Pubitemid 36593307)
3. Bartsch H, Malaveille C, Lowenfels AB, Maisonneuve P, Hautefeuille A, Boyle P (1998). Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. Eur J Cancer Prev 7:215-223. (Pubitemid 28318342)
4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101.
5. Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP (2006). A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev 15:2422-2426. (Pubitemid 46048299)
6. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:979-987. (Pubitemid 43823527)
7. Chen DJ, Ding R, Cao W, Ye DQ (2011). Interaction between polymorphisms in NQO1 C609T and XRCC1 G28152A and their correlation with smoking on gastric cancer in Chinese. Chin J Epidemiol 30:5-8.
8. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735-6740. (Pubitemid 23006271)
9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188. (Pubitemid 17189972)
10. Di Martino E, Hardie LJ, Wild CP, Gong YY, Olliver JR, Gough MD, et al. (2007). The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med 9:341-347. (Pubitemid 46956476)
11. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634. (Pubitemid 27387172)
12. Feng XX, Li ZF, Wang LB, Zhang JB, Lu ZX (2008). Study on the relationship between polymorphism of NQO1 gene and susceptibility to esophageal cancer in Chinese. Chin J Dis Control Prev 12:112-114.
13. Gonzalez CA, Riboli E (2010). Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 46:2555-2562.
14. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA (2008). NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol 168:1221-1232.
15. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, et al. (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7:103-108. (Pubitemid 34538454)
16. Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T (2000). NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 73:528-531. (Pubitemid 30062483)
17. Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, Vodicka P, et al. (2010). Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 24:1347-1353.
18. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, et al. (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis 26:1122-1128. (Pubitemid 41214306)
19. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001). Replication validity of genetic association studies. Nat Genet 29:306-309. (Pubitemid 33096456)
20. Joseph P, Jaiswal AK (1994). NAD(P)H:quinone oxidoreductase1 (DT diaphor-ase) specifically prevents the formation of benzoapyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 91:8413-8417. (Pubitemid 24273674)
21. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, et al. (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76:852-854. (Pubitemid 27401934)
22. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM (1995). Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72:555-561.
23. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, et al. (2000). NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogen-esis 21:1813-1819.
24. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. (2005). A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15:535-546. (Pubitemid 41044239)
25. Li Y, Zhang JH, Guo W, Wang R, Wen DK, Wei LZ (2004). Association between NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and cancer of gastric cardia risk in Chinese. Zhonghua Liu Xing Bing Xue Za Zhi 25:731.
26. Liu L, Wu C, Wang Y, Zhong R, Wang F, Zhang X, et al. (2011). Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32:336-342.
27. Liu L, Zeng F, Wang K, Huang J, Xin L, Zhu PQ (2011). Meta-analysis of the association between VEGF-634 G > C and risk of malignancy based on 23 case-control studies. J Cancer Res Clin Oncol 137:1027-1036.
28. Malik MA, Zargar SA, Mittal B (2011). Role of NQO1 609C> T and NQO2-3423G > A polymorphisms in susceptibility to gastric cancer in Kashmir Valley. DNA Cell Biol 30:297-303.
29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
30. Marjani HA, Biramijamal F, Rakhshani N, Hossein-Nezhad A, Malekzadeh R (2010). Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A case-control study from Iran. Genet Mol Res 9:239-249.
31. Misra V, Grondin A, Klamut HJ, Rauth AM (2000). Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer 83:998-1002.
32. Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, Atkin WS, et al. (2007). Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis 28:875-882. (Pubitemid 46523343)
33. Navarro Silvera SA, Mayne ST, Risch HA, Gammon MD, Vaughan T, Chow WH, et al. (2011). Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol 21:543-550.
34. Nisa H, Kono S, Yin G, Toyomura K, Nagano J, Mibu R, et al. (2010). Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. BMC Cancer 10:274.
35. Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, Carey FA, et al. (2010). Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20:315-326.
36. Ren JJ, Yang XH, sU XL (2006). NAD(P)H: quinone oxidoreductase gene polymorphism association with gastric carcinoma in Chinese. Zhong hua Zhong Liu Fang Zhi Za Zhi 11:1686-1688.
37. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D (2000). NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactiva-tion, gene regulation and genetic polymorphisms. Chem Biol Interact 129:77-97. (Pubitemid 32061055)
38. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. (2002). A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23:1839-1849. (Pubitemid 35363272)
39. Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA (2010). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev 11:209-213.
40. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, et al. (2003). Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107:381-386. (Pubitemid 37266457)
41. Tijhuis MJ, Visker MH, Aarts JM, Laan W, de Boer SY, Kok FJ, et al. (2008). NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer 122:1842-1848. (Pubitemid 351413432)
42. Van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, et al. (2006). Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593:39-49. (Pubitemid 43113361)
43. Von Rahden BH, Stein HJ, Langer R, von Weyhern CW, Schenk E, Doring C, et al. (2005). C609Tpolymorphism of the NAD(P)H:quinone oxidoreductase I gene does not significantly affect susceptibility for esophageal adenocarci-noma. Int J Cancer 113:506-508. (Pubitemid 40038723)
44. Vrieling A, Kampman E (2010). The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr 92:471-490.
45. Watanabe RM (2011). Statistical issues in gene association studies. Methods Mol Biol 700:17-36.
46. Yu X, Zhang T, Zhang H, Hu A, Hu Y, Guo W, et al. (2010). Comparison of lifestyle and living environment among high risk immigrant and low risk host residents: implications for esophageal cancer etiology. Asian Pac J Cancer Prev 11:1827-1831.
47. Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, et al. (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 125:467-472.
48. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, et al. (2003a). Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 24:905-909. (Pubitemid 36748907)
49. Zhang JH, Li Y, Wang R, Geddert H, Guo W, Wen DG, et al. (2003b). NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 9: 1390-1393. (Pubitemid 36992319)
50. Zhou YL, Chen HF, Shi XS, Zhou ZX, Li GL, Pan PC, et al. (2006). A case-control study on the polymorphisms of NQO1 and susceptibility of esophageal cancer in Chinese. Zhonghua Zhong Liu 15:659-663.
51. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, et al. (2010). Interleukin 10-592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci 55:1525-1532.